AstraZeneca sells £2.7bn block to fund cancer drug deal
Pharmaceutical giant AstraZeneca has entered into a collaboration agreement with Japanese pharmaceutical company Daiichi Sankyo to develop a new antibody-drug conjugate which it is hoped will revolutionise cancer treatment. The deal is being funded through an equity capital raise.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
- ✔ 4,000 annual insights
- ✔ 700+ notes and long-form analyses
- ✔ 4 capital markets databases
- ✔ Daily newsletters across markets and asset classes
- ✔ 2 weekly podcasts